Previous Article | Next Article ![]()
Infection and Immunity, August 2003, p. 4250-4259, Vol. 71, No. 8
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.8.4250-4259.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Orhan Sahin,
Linda Overbye Michel, and Qijing Zhang*
Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University, Wooster, Ohio 44691
Received 7 February 2003/ Returned for modification 8 April 2003/ Accepted 12 May 2003
|
|
|---|
|
|
|---|
Campylobacter jejuni is the leading bacterial cause of human enteritis in many industrialized countries (13). The majority of human infections result from consumption of undercooked poultry meat or other food products cross-contaminated with raw poultry meat during food preparation (47). As an enteric pathogen, C. jejuni enters the host intestine via oral ingestion and colonizes the distal ileum and colon. Once inside the intestine, C. jejuni is faced with multiple levels of stresses, such as the action of antimicrobial bile salts and peptides, starvation (e.g., iron limitation), competition with other residential flora, antibiotic treatments, and attack by host immune defenses. Campylobacter must counteract these harsh conditions in order to survive and multiply in an animal host. In the past decades, many efforts have been directed to understanding the virulence factors involved in Campylobacter adhesion, invasion, and cytotoxicity. Some known examples of putative virulence elements include CDT toxins (18, 19, 26), PEB1 (38), CadF (23), Fla (15, 35), JlpA (22), Cia proteins (24, 43), the pVir plasmid (4), and a phase-variable capsule (5), of which the motility-mediating flagellum (Fla) is the best-characterized virulence factor shown to be required for Campylobacter colonization in the gastrointestinal tract of birds and mammals (15, 34, 35, 37, 50). Despite these advances in understanding the pathobiology of Campylobacter pathogenesis, little is known about the mechanisms utilized by Campylobacter to adapt in the intestinal environment in the presence of various antimicrobial agents, such as bile salts. Understanding the adaptation mechanisms may facilitate the development of effective means to prevent and control Campylobacter infection in humans and animal reservoirs.
Recently, a Campylobacter multidrug efflux pump (named CmeABC) contributing to antimicrobial resistance was characterized (28, 31, 42). This efflux pump is chromosomally encoded by a three-gene operon (cmeABC) and shares significant sequence and structural homology with known tripartite multidrug efflux pumps in other gram-negative bacteria. Based on the sequence and structural homology with known bacterial efflux pumps, it was predicted that CmeA, CmeB, and CmeC are a periplasmic protein, an inner membrane drug transporter, and an outer membrane protein, respectively. It is believed that the three members function together and form a membrane channel for the extrusion of antimicrobials and other toxic compounds in Campylobacter (28). An insertional mutation in cmeB of various Campylobacter strains resulted in substantial decreases in Campylobacter resistance to various antimicrobials (28, 31, 42). Accumulation assays demonstrated that CmeABC functions as an energy-dependent efflux pump in C. jejuni. PCR and immunoblotting showed that cmeABC is broadly distributed and constitutively expressed in various Campylobacter isolates grown in Mueller-Hinton (MH) broth. Our previous findings (28) also suggested that CmeABC may be an important player in bile resistance, which prompted us to determine its role in the adaptation of Campylobacter to the intestinal environment of an animal host. Using both in vitro and in vivo systems, we demonstrated in this study that CmeABC, by mediating bile resistance, is essential for Campylobacter growth in bile-containing media and in colonization in animal intestinal tracts. These findings define a key natural function of a multidrug efflux pump in an enteric pathogen and open new avenues for the development of measures to control Campylobacter infection in humans and in animal reservoirs.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Bacterial plasmids and strains used in this study
|
![]() View larger version (51K): [in a new window] |
FIG. 1. Immunoblot analysis of CmeB and CmeC expression in wild-type 21190 and various cmeABC mutant constructs. Cell envelopes prepared from C. jejuni 21190 (lane 2), JL101 (lane 3), JL102 (lane 4), JL103 (lane 5), and JL104 (lane 6) were blotted with specific antibodies against CmeB (A) and CmeC (B). Similar amounts of total proteins were loaded in each lane. Prestained molecular mass markers (lane 1; Bio-Rad) were coelectrophoresed and blotted to allow estimation of the sizes of the proteins.
|
Susceptibility tests. The MICs of different bile salts, fatty acids, and detergents for C. jejuni 21190 and its cmeABC mutant constructs were determined using a microtiter broth dilution method as described in a previous publication (28). The compounds utilized in these assays were purchased from Sigma Chemical Co. (cholic acid, chenodeoxycholic acid, taurocholic acid, deoxycholic acid, dehydrocholic acid, glycocholic acid, taurodeoxyxholic acid, choleate, capric acid, butyric acid, palmitic acid, and Triton X-100), EM Science (sodium dodecyl sulfate [SDS]), Calbiochem (Empigen BB), and Amresco (Tween 20).
Preparation of chicken intestinal extracts. Ten 21-day-old broiler chickens were used for the preparation of chicken intestinal extracts. All birds tested negative for Campylobacter by culturing cloacal swabs. Chicken intestinal extracts were prepared from three different sections of the intestine, including the duodenum, jejunum, and cecum. The intestinal contents from each section were pooled from the 10 chickens. Each pool of chicken intestinal contents was divided in half, and each half was resuspended in the same volume of MH broth or saline by vortex, followed by centrifugation at 10,000 x g at 4°C for 30 min. The supernatant from the MH or saline extraction was sterilized by successive filtration through a series of membrane filters (prefilter 1.2 µm and 0.45 µm; Millipore Co.). The filtered intestinal extracts were tested for sterility by plating 200 µl of the final filtrate on MH plates and incubating the plates under aerobic and microaerophilic conditions for 3 days, which showed there was no growth of any bacterial colony. The filtered intestinal extracts were used for measuring bile salt concentrations (saline-based extracts) and for in vitro growth inhibition assays (MH-based extracts).
Measurement of total bile salt concentrations. Total bile concentrations in chicken duodenal, jejunal, and cecal extracts were measured using a total bile acids assay kit according to the procedure supplied by the manufacturer (Diazyme, San Diego, Calif.). The concentration (expressed as millimolar) of bile salts in each intestinal extract was recorded as the mean of four measurements.
In vitro growth assay.
To compare the growth characteristics of C. jejuni 21190 and its cmeABC mutants in the presence of bile salts and chicken intestinal extracts, an in vitro growth assay was performed in microtiter plates. Each well of the plate contained 225 µl of medium plus 25 µl of Campylobacter inoculum (approximately 5 x 106 CFU/ml). Several media were used for the assays, including MH, MH supplemented with sodium choleate (1 mg/ml;
2 mM bile salts), and MH-based chicken intestinal extracts. We chose sodium choleate (Sigma) for the in vitro assay because it is a crude ox bile extract that contains the sodium salts of cholic, glycocholic, deoxycholic, and taurocholic acids, which closely reflect the bile salt components in animal intestine. Triplicate wells were used for each strain and mutant. The cultures were incubated at 42°C under microaerophilic conditions for 48 h. During the incubation, samples were taken at different time points (1, 3, 7, 12, 24, and 48 h postinoculation), serially diluted, and plated on MH agar for enumeration of Campylobacter colonies in each sample. The log10-transformed CFU for each sample was used to compare the growth of various strains and mutants in different media.
Chicken colonization experiments. Newly hatched day-old broiler chickens were obtained from a commercial hatchery. Prior to use, these chicks were screened for Campylobacter by culturing cloacal swabs, which were plated onto MH agar plates containing Campylobacter-specific growth supplements (SR084E and SR117E; Oxoid). All of the birds tested negative for Campylobacter. To compare the wild-type 21190 and its cmeABC mutant constructs, 48 2-day-old birds were assigned to four treatment groups (12 birds/group). Each group was inoculated with a similar dose (106 CFU/chicken, via oral gavage) of wild-type 21190, JL101, JL102, or JL103. Each group of chickens was maintained in a sanitized wire-floored cage and provided with unlimited access to feed and water. The feed (C-2-88; Ohio Agricultural Research and Development Center, Ohio State University) was manufactured on site and was Campylobacter-free and without any animal protein or antibiotic additives. The parent strain and cmeABC mutants showed similar growth patterns in the feed extract (data not shown). Thus, the feed should not be a factor influencing the growth of cmeABC mutants in the intestine. Because the chickens were given city water, which contained sodium hypochlorite at a concentration of 5 ppm, we also determined if CmeABC influences Campylobacter susceptibility to sodium hypochlorite. Wild-type 21190 and cmeABC mutants had the same MIC of 262 ppm for sodium hypochlorite, which is well above the chlorine concentration in the city water. In addition, both the wild type and the mutants showed similar survival patterns in fresh drinking water from the chicken house (data not shown). Thus, the feed and drinking water were not factors influencing the survival of cmeABC mutants in the chickens.
Fecal samples were collected using cloacal swabs, which were taken every 2 days and diluted in MH broth for enumeration of Campylobacter cells. For the groups inoculated with wild-type 21190 and JL103, each fecal suspension was plated onto MH plates containing Campylobacter-specific growth supplements (Oxoid) for counting Campylobacter colonies. Since inactivation of cmeABC makes Campylobacter become susceptible to rifampin (28), a selective agent present in the Campylobacter-specific growth supplement (SR117E; Oxoid), the standard selective medium was not suitable for the isolation of JL101 and JL102. Therefore, the selective medium was modified by replacing rifampin with kanamycin and retaining the other three selective agents present in the growth supplement, including trimethoprim (10 µg/ml), cycloheximide (100 µg/ml), and polymyxin B (1 µg/ml), which are not substrates of CmeABC (28). This modified selective medium fully supported the growth of JL101 and JL102 in pure culture or spiked fecal samples (data not shown). This modified medium was used for isolation of Campylobacter from chickens inoculated with JL101 or JL102.
To determine the minimum infective dose of C. jejuni 21190 and JL101, 40 2-day-old broilers were assigned to eight groups (five birds/group), four of which were inoculated with various doses of wild-type 21190 (1.2 x 104 to 1.2 x 107 CFU/chicken). The other four groups were inoculated with different doses of JL101 (3.2 x 106 to 3.2 x109 CFU/chicken). After inoculation, cloacal swabs were collected from the chickens and cultured for Campylobacter. The minimum infective dose was defined as the lowest dose at which at least one chicken of the inoculated group was colonized within 2 weeks after inoculation.
Immunoblotting analysis of CmeABC expression. Expression of cmeABC in JL101, JL102, JL103, and JL104 was examined using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting as described previously (28). Immunoblotting was performed to determine if CmeABC was expressed and immunogenic in vivo. The recombinant proteins for CmeA, CmeB, and CmeC were generated in a previous study (28). The recombinant proteins were separated by SDS-PAGE and were then electrophoretically transferred to a nitrocellulose membrane as described previously (28). The blots were incubated with chicken serum samples (1:100 dilution in blocking buffer), which included three negative control serum samples from 3-week-old Campylobacter-free broiler chickens and eight serum samples from 2-year-old specific-pathogen-free layers or 6-week-old broilers experimentally infected with C. jejuni (46). After incubation at 25°C for 1 h, the blots were washed three times with phosphate-buffered saline containing 0.05% Tween 20 and subsequently incubated with secondary antibodies (1:1,000 dilution of goat anti-chicken immunoglobulin G-horseradish peroxidase; Kirkegaard & Perry) at 25°C for 1 h. After washing, the blots were developed with the 4 CN membrane peroxidase substrate system (Kirkegaard & Perry).
|
|
|---|
|
View this table: [in a new window] |
TABLE 2. Susceptibilities of strain 21190 and its mutant constructs to different bile salts, fatty acids, and detergents
|
Inhibition of Campylobacter growth by choleate.
To further examine the contribution of CmeABC in bile resistance, we compared the in vitro growth characteristics of 21190 and its cmeABC mutants in MH broth or MH broth containing 1 mg of choleate/ml (
2 mM bile salts). In conventional MH broth, both the wild-type strain and the mutants showed similar growth patterns (Fig. 2A). However, addition of choleate in MH broth greatly inhibited the growth of JL101 and JL102, but it did not have any effect on wild-type 21190 (Fig. 2B). In fact, no viable JL101 and JL102 cells were detected after 3 h of incubation in MH broth with choleate (Fig. 2B). Complementation of JL101 with pCME (JL103) completely restored the growth of the mutant to the wild-type level in MH broth supplemented with choleate (Fig. 2B). Together, these results indicate that the CmeABC pump is essential for Campylobacter growth in bile salts-containing medium in vitro.
![]() View larger version (26K): [in a new window] |
FIG. 2. Effects of bile salts and chicken intestinal extracts on the in vitro growth of C. jejuni 21190 and its isogenic cmeABC mutants. Bacteria were grown in MH broth (A), MH broth supplemented with sodium choleate (1 mg/ml) (B), chicken duodenal extract (C), chicken jejunal extract (D), and chicken cecal extract (E). The downward arrow indicates that no viable colonies were detected in the experiments, and the detection limit of the method was 10 CFU/ml. Each data point represents the mean value obtained from triplicate wells in the microtiter plate growth assay.
|
To determine if chicken intestinal extracts inhibited the growth of Campylobacter, wild-type 21190, JL101, JL102, and JL103 cells were grown in MH-based intestinal extracts. As shown in Fig. 2, the growth of JL101 and JL102 was greatly inhibited compared with that of wild-type 21190, although each intestinal extract showed a unique inhibitory pattern on Campylobacter growth. The wild-type strain grew normally in chicken duodenal extract as in MH broth, but the mutants did not show any growth. In fact, no viable JL101 and JL102 cells were detected after 24 h of incubation (Fig. 2C). Unlike the duodenal extract, the jejunal extract not only showed a striking bactericidal effect on the mutants but also had strong growth inhibition for wild-type 21190 (Fig. 2D). However, the two mutants experienced much faster and greater growth reductions than the wild-type strain in the jejunal extract. After 3 h of incubation, both JL101 and JL102 were no longer detected, suggesting that the jejunal extract killed the mutants within 3 h. On the contrary, wild-type 21190 did not show any growth reduction for the first 6 h, had 1 log unit of growth reduction by 12 h of incubation, and was below the detection limit by 24 h of incubation (Fig. 2D). In the cecal extract, which had the lowest bile concentration, wild-type 21190 grew normally and reached stationary phase within 24 h (Fig. 2E). However, JL101 and JL102 failed to grow in the cecal extract, although both of them survived longer than in the duodenal extract. As shown with JL103, complementation of the cmeB mutant with pCME fully restored the growth of the mutant to the wild-type level in each of the three intestinal extracts (Fig. 2). Additional experiments conducted at different times also showed similar growth patterns for 21190 and its cmeABC mutants as described above (data not shown). In addition, the cmeABC mutants of strain 81-176 also showed growth defects in the chicken intestinal extracts (data not shown). The overall inhibitory effect of each intestinal extract on Campylobacter growth was well correlated with the bile concentration in each preparation. These results clearly demonstrated that CmeABC is essential for Campylobacter survival and growth in chicken intestinal extracts.
CmeABC is essential for the colonization of Campylobacter in chickens. The inability of JL101 and JL102 to grow in the intestinal extracts suggested that CmeABC may be required for Campylobacter adaptation in chickens. To test this possibility, a typical chicken colonization model was used to determine the role of CmeABC in the colonization of C. jejuni. As shown in Fig. 3, wild-type 21190 colonized the chickens as early as 2 days postinoculation, and the majority of chickens were colonized at day 8 postinoculation as determined by culturing cloacal swabs. In individual chickens, the density of the organism was as high as 107 CFU/g of feces. In contrast, C. jejuni was not detected throughout the study in any of the cloacal samples collected from the chickens inoculated with JL101 or JL102 (Fig. 3). The construct JL103 displayed a colonization rate and shedding level comparable with those of wild-type 21190 (Fig. 3).
![]() View larger version (20K): [in a new window] |
FIG. 3. Colonization of C. jejuni 21190 and its isogenic cmeABC mutants in chickens. (A) Percentage of chickens colonized by C. jejuni after inoculation. (B) The shedding level of Campylobacter in chickens colonized by C. jejuni after inoculation. Each data point represents the mean CFU of the colonized chickens in each group. Standard errors are indicated by error bars.
|
|
View this table: [in a new window] |
TABLE 3. Determination of the minimum infective dose of 21190 and JL101 in broiler chickens
|
CmeABC is expressed and immunogenic in vivo. To determine if CmeABC is expressed and immunogenic in vivo, immunoblotting was performed using purified recombinant CmeABC peptides and serum samples from chickens infected with Campylobacter. As shown in Fig. 4A, the serum from a Campylobacter-infected chicken showed positive reaction to recombinant CmeA, CmeB, and CmeC, while the serum from a Campylobacter-free chicken did not react with any of the three recombinant proteins. Furthermore, multiple chicken sera were tested for reactivity with recombinant CmeC (Fig. 4B). All eight sera from Campylobacter-infected chickens showed a vivid antibody reactivity to recombinant CmeC (Fig. 4B), which is a predicted outer membrane component of the CmeABC efflux system. All the sera from Campylobacter-free chickens were negative for CmeC (Fig. 4B, lanes 11 to 13). These results suggest that CmeABC is expressed during Campylobacter infection of chickens and elicits a specific antibody response in the host.
![]() View larger version (55K): [in a new window] |
FIG. 4. Immunoblot analysis of in vivo antibody responses to CmeABC. (A) Purified recombinant CmeA (lanes 2 and 6), CmeB (lanes 3 and 7), and CmeC (lanes 4 and 8) peptides were blotted with serum from a chicken infected with C. jejuni (lanes 1 to 4) or serum from a Campylobacter-free chicken (lanes 5 to 8). (B) The recombinant CmeC was blotted with the rabbit anti-CmeC antibody (lane 2) or with individual chicken serum samples (lanes 3 to 13). Lanes 3 to 6, serum samples from 2-year-old Campylobacter-infected specific-pathogen-free layers; lanes 7 to 10, serum samples from 6-week-old broiler chickens infected with C. jejuni; lanes 11 to 13, serum samples from 3-week-old broiler chickens which were free of Campylobacter. Prestained molecule mass markers (lanes 1 and 5 in panel A and lane 1 in panel B; Bio-Rad) were coelectrophoresed and blotted to allow estimation of the sizes of the proteins.
|
|
|
|---|
Bile salts are detergent-like amphipathic molecules normally present in animal intestinal tracts. As surface-active detergents, bile salts have potent antimicrobial activity (16, 20, 21). The major species of bile salts produced by the liver are the taurine and glycine conjugates of cholic acid and chenodeoxycholic acid, which are known as primary bile salts (2). These bile salts undergo further structural modifications (e.g., deconjugation and dehydroxylation) and result in various bile acid metabolites (e.g., cholic acid, chenodeoxycholic acid), which are known as secondary and tertiary bile salts (2). Under conditions existing in the gut of humans and animals, the bile concentration can be as high as 23 mM in jejunum, although a concentration of 2 mM is generally considered to be necessary for the formation of micelles for lipid digestion (10, 14, 51). The high concentration of bile salts in chicken small intestine (duodenum and jejunum) constitutes a formidable barrier for Campylobacter, and even the wild-type 21190 experienced a significant reduction in viability after 12 h of incubation in the jejunal extract (Fig. 2). Although the filtrates of chicken intestinal contents may not represent the microenvironment in which C. jejuni lives in the chicken intestinal tract, the inhibitory effect of the jejunal extract on Campylobacter growth is consistent with the fact that Campylobacter is rarely isolated from the small intestine of chickens (1, 6). In the cecum, the predominant site for Campylobacter colonization in chickens, the bile concentration is low enough to allow the growth of wild-type Campylobacter and high enough to inhibit the growth of cmeABC mutants (Fig. 2). This in vitro observation was consistent with the in vivo result that mutants JL101 and JL102 failed to colonize the intestinal tract (Fig. 3 and Table 3). Together, these findings strongly indicate that Campylobacter needs a functional CmeABC for growth in the gut.
To determine the substrate spectrum of the CmeABC system, we also investigated the role of CmeABC in the resistance to nonbile detergents as well as hydrophobic fatty acids. Strikingly, mutations in cmeABC resulted in much greater MIC reductions for nonionic detergents (Triton X-100 and Tween 20) than those for an ionic detergent (SDS) or zwitterionic detergent (Empigen). The susceptibility test conducted in this study revealed that CmeABC has a limited role in the efflux of fatty acids, suggesting that fatty acid resistance is an unlikely mechanism by which CmeABC contributes to Campylobacter adaptation in vivo. It should be pointed out that the MIC changes observed in JL101 and JL102 were not attributable to pH. All fatty acids and bile salts used in this study are sodium salts, and their pH is approximately 7.0 after solubilization in MH broth for the MIC test (data not shown). In addition, wild-type 21190 and JL101 grew similarly in acidic MH medium (pH 5.0), suggesting that CmeABC is not involved in resistance to acidic stress.
The chicken is a natural host and major reservoir for C. jejuni. This organism is well adapted to the intestinal tract of poultry, which provides an excellent model for evaluating Campylobacter colonization (not a model for disease). Colonization of chickens by C. jejuni occurs mainly in lower intestines, where the organism mainly infects cecal and cloacal crypts (1, 6, 33). Unlike the infection in mammals (e.g., mice, swine, rabbits, monkeys, and humans), in which C. jejuni may invade intestinal epithelial cells and cause histopathologic changes (3, 8, 44, 45), infection of chickens by C. jejuni does not result in invasion of the intestinal epithelium and clinical disease under normal conditions (6, 33). Newly hatched chickens are usually Campylobacter-free, eliminating the potential contamination of experimental chickens by unknown Campylobacter strains. Using this chicken model, we demonstrated the essential role of CmeABC in in vivo colonization. To exclude the possibility that the colonization deficiency of cmeABC mutants was due to factors that are not related to bile resistance, we evaluated bacterial growth in feed extract and drinking water (detailed in Materials and Methods). Both wild-type 21190 and cmeABC mutants showed similar growth and survival patterns in the feed and drinking water. These observations further support our conclusion that the key role of CmeABC in Campylobacter colonization is related to bile resistance.
Efflux of antibiotics by MDR pumps is considered an opportunistic function of the pumps, and the natural functions of MDR efflux systems are still largely unknown (36, 39, 40). Previous studies using in vitro assays indicated that AcrAB of Escherichia coli (12, 32, 48), MtrCDE of Neisseria gonorrhoeae (17), and VceAB of Vibrio cholerae (9) are involved in the resistance to bile and/or fatty acids, suggesting that these MDR pumps may provide a protective role in the survival of pathogens in the gut or other mucous sites. However, these studies lack direct evidence showing the role of efflux pumps in the in vivo adaptation of these pathogenic bacteria. Work presented in this study provides direct evidence showing the in vivo protective function of CmeABC by mediating bile resistance. According to this observation plus our previous finding (28) that CmeABC is broadly distributed and expressed in Campylobacter strains from various sources, it can be concluded that bile resistance is an important natural function for CmeABC. Despite the constitutive expression of CmeABC in wild-type C. jejuni strains, it is possible that CmeABC is subject to regulation by other factors. This speculation is based on the finding of a putative transcriptional repressor gene occurring immediately upstream of cmeA and the presence of a putative operator in the intergenic region between cmeA and its upstream open reading frame (28). However, immunoblotting analysis of Campylobacter cells grown in the presence or absence of cholic acid did not reveal obvious differences in the expression of CmeABC (data not shown). At this stage, it is unknown if CmeABC could be regulated by other bile salts or other substrates. Investigation of the regulatory mechanism of CmeABC will further improve our understanding of the function of CmeABC in the adaptation of Campylobacter in various niches.
It has been proposed that inhibiting MDR efflux systems is one approach to enhance drug accumulation inside the bacterial cell, thereby increasing bacterial susceptibility to antimicrobials (30, 41). Recently, MDR efflux pump inhibitors have been developed and demonstrated to potentiate the activity of antimicrobial agents against a range of gram-negative bacteria (29, 30). The presence of such inhibitors also resulted in a decreased frequency of emergence of Pseudomonas aeruginosa strains that are highly resistant to fluoroquinolones (29). Based on the findings from this study, we speculate that inhibitors targeting the CmeABC efflux pump may not only control antibiotic resistance but also increase the susceptibility of C. jejuni to in vivo bile salts, consequently decreasing the colonization level of Campylobacter. Such pump inhibitors could be directly used as novel antimicrobials for therapeutic intervention of Campylobacter infection. Inhibiting bacterial efflux of bile salts with pump inhibitors in the gut may be a general approach for developing therapeutic measures for enteric pathogens. From the standpoint of vaccine development, the outer membrane components of MDR pumps of gram-negative bacteria may be exploited as the targets of immune interventions, preventing the development of antibiotic resistance and the establishment of in vivo infection (27). In this study, we demonstrated that the outer membrane component CmeC is expressed and immunogenic in vivo, supporting the feasibility of targeting CmeC for immune protection against Campylobacter colonization. This possibility remains to be examined in future studies.
DNA sequences were determined at the Molecular, Cellular, and Imaging Center of the Ohio Agricultural Research and Development Center at The Ohio State University.
Present address: Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA 50011. ![]()
Permanent address: Department of Microbiology, Veterinary Faculty, Mustafa Kemal University, Hatay, Turkey. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»